Phase II trial evaluating the combination of eribulin (E) plus bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study

被引：0

作者：

Hardy-Bessard, A-C. ^{[1
]}

Brocard, F. ^{[2
]}

Leheurteur, M. ^{[3
]}

Melis, A. ^{[4
]}

Dauba, J. ^{[5
]}

Lortholary, A. ^{[6
]}

You, B. ^{[7
]}

Guardiola, E. ^{[8
]}

Grenier, J. ^{[9
]}

Martin-Babau, J. ^{[10
]}

Meunier, J. ^{[11
]}

Follana, P. ^{[12
]}

Savoye, A-M. ^{[13
]}

Mercier-Blas, A. ^{[14
]}

Marti, A. ^{[15
]}

Despax, R. ^{[16
]}

Barbier, N. ^{[17
]}

Gane, N. ^{[18
]}

Ardisson, P. ^{[19
]}

Segura-Djezzar, C. ^{[20
]}

机构：

[1] Ctr CARIO HPCA, Oncol Med, Plerin Sur Mer, France

[2] ORACLE Ctr Oncol Gentilly, Oncol Med, Nancy, France

[3] Ctr Henri Becquerel, Oncol Med, Rouen, France

[4] Hop Prive St Marie, Oncol Med, Chalon Sur Saone, France

[5] Hop Mt de Marsan, Oncol Med, Mt De Marsan, France

[6] Ctr Catherine Sienne, Oncol, Nantes, France

[7] Ctr Hosp Lyon Sud, Oncol Med, Pierre Benite, France

[8] CH Dracenie Draguignan, Oncol Med, Draguignan, France

[9] Inst Ste Catherine, Cancerol Clin, Avignon, France

[10] Hop Morvan, CHU Brest, Inst Cancerol & Hematol, Brest, France

[11] CHR Orleans Source, Oncol Med, Orleans, France

[12] Ctr Antoine Lacassagne, Oncol Med, Nice, France

[13] Inst Jean Godinot, Serv Rubis Oncol Med, Reims, France

[14] Ctr Hosp Prive St Gregoire, Oncol Med, St Gregoire, France

[15] CH Auxerre, Serv Oncol, Auxerre, France

[16] Clin Pasteur ONCOSUD, Oncol Hematol, Toulouse, France

[17] Clin St Pierre, Oncol Med, Ctr Catalan Oncol, Perpignan, France

[18] Arcagy Gineco, Serv Biostat, Paris, France

[19] Clin Sauvegarde, Serv Chimiotherapie, Lyon, France

[20] Ctr Francois Baclesse, Oncol Med, Caen, France

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw365.14

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

235P

引用

页数：1